Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities.
In fact, says the company, researchers spend a considerable amount of time on tasks that could be more efficiently and effectively executed by automation. Collaborative engagement with expert-led CROs can provide more productive and successful processes, with research scientists spending more time reading the literature, designing higher-value experiments and interpreting results.
DDW hosted this webinar, supported by BMG Labtech and Arctoris: COVID targets in the crosshairs: Unparalleled quality and speed from Arctoris’ Ulysses platform.
You can watch on demand for FREE here.
The event will feature the expertise of Dr Daniel Thomas, Head of Discovery Biology, Arctoris, and Catherine Wark, Applications Manager, BMG Labtech.
This webinar will discuss:
- How automated experimental and analytical workflows can deliver superior quality data and expedite project timelines
- Three Covid-19 case study examples to highlight the attainable data quality
- How state-of-the-art microplate readers support robust assay performance
Who should attend:
- Biotechs with focus on anti-viral drug development and molecular virology and cellular response and/or new approaches to improve efficiency.
- Pharma industry and CRO with focus on anti-viral drugs discovery and/or new approaches to improve efficiency.
